L. Trinh

发表

Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.

C. Ly, S. Sideris, S. Malek, 2011, Journal of medicinal chemistry.

Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.

C. Ly, S. Sideris, S. Malek, 2012, Journal of medicinal chemistry.

Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19

M. Peluso, Jeffrey N. Martin, T. Wrin, 2021, medRxiv.

Novel Method To Assess Antiretroviral Target Trough Concentrations Using In Vitro Susceptibility Data

C. Petropoulos, N. Parkin, E. Acosta, 2012, Antimicrobial Agents and Chemotherapy.

Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.

N. Parkin, D. Irlbeck, L. Trinh, 2009, The Journal of infectious diseases.

Identification of a series of potent telomerase inhibitors using a time‐resolved fluorescence‐based assay

J. Devlin, L. Bare, L. Trinh, 1998 .

Solid-phase synthesis of naphthylamidines as factor VIIa/tissue factor inhibitors.

M. Morrissey, M. McCarrick, D. Light, 2005, Bioorganic & medicinal chemistry letters.

Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.

M. Whitlow, D. Davey, K. Eagen, 1998, Journal of medicinal chemistry.

Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors.

D. Davey, K. Eagen, M. Morrissey, 2003, Bioorganic & medicinal chemistry letters.

Solid-phase synthesis of N-substituted amidinophenoxy pyridines as factor XA inhibitors.

M. Morrissey, B. Buckman, R. Mohan, 1998, Bioorganic & medicinal chemistry letters.

Discovery and characterization of a potent and selective non-amidine inhibitor of human factor Xa.

J. Morser, D. Light, M. Kochanny, 2003, Biochemical pharmacology.

Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.

A. Beatty, M. Whitlow, D. Davey, 1999, Journal of medicinal chemistry.

High capacity screening of pooled compounds: Identification of the active compound without re‐assay of pool members

Richard Spann, Wei Zheng, Jason Kondracki, 1996 .

Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors.

M. Whitlow, M. Morrissey, S. Sakata, 2000, Bioorganic & medicinal chemistry letters.

Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.

D. Arnaiz, L. Trinh, K. Shaw, 2000, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological activity of novel factor Xa inhibitors: 4-aryloxy substituents of 2,6-diphenoxypyridines.

K. Eagen, M. Morrissey, G. Phillips, 2002, Bioorganic & medicinal chemistry.

Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.

M. Morrissey, B. Buckman, R. Mohan, 1998, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.

M. Morrissey, B. Buckman, R. Mohan, 1998, Bioorganic & medicinal chemistry letters.

Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms

M. Peluso, Jeffrey N. Martin, T. Wrin, 2021, Cell Reports.

SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay

M. Peluso, Jeffrey N. Martin, T. Wrin, 2021, Science Advances.

SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay

12, M. Peluso, Jeffrey N. Martin, 2021, medRxiv.

Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase.

J. Haeggström, M. Adler, M. Whitlow, 2008, Bioorganic & medicinal chemistry.

The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition.

D. Ruderman, H. Dinter, Jianhuan Zhang, 2007, Neoplasia.

Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR).

S. Sideris, L. Friedman, S. Malek, 2013, Journal of medicinal chemistry.

Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.

M. Belvin, C. Ly, S. Sideris, 2013, ACS medicinal chemistry letters.

Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5

T. Wrin, N. Parkin, J. Larson, 2008 .

Development of an Immunofluorometric, High-Capacity, Cell-Based Assay for the Measurement of Human Type I and Type II Interferons

E. Croze, R. Snider, D. Watling, 1999, Journal of biomolecular screening.

Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.

M. Whitlow, D. Arnaiz, L. Trinh, 2000, Bioorganic & medicinal chemistry letters.

Design and synthesis of aminophenol-based factor Xa inhibitors.

W. Xu, M. Morrissey, S. Sakata, 2002, Bioorganic & medicinal chemistry letters.